NCT00733551

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.

A Randomized, Double-blind, Ascending Dose Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Repeat Doses of Motilin Receptor Agonist GSK962040 in Male and Female Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses of GSK962040.

Conditions

• Gastroparesis

Interventions

Type	Name	Description
DRUG	GSK962040	GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
DRUG	Placebo	Placebo tablets will be given orally, once daily, in the morning, in a fasted state.

Timeline

• Start date: 2008-09-23
• Primary completion: 2009-07-20
• Completion: 2009-07-20
• First posted: 2008-08-13
• Last updated: 2017-07-18

Locations

1 site across 1 country: United Kingdom